Fund shareholders of CYTOMX THERAPEUTICS INC
ISIN US23284F1057 · United States · LEI 5493004VW2FW0QLL3345
- Fund shareholders
- 144
- Of which ETFs
- 32 112 other funds
- Value held
- ≈ 228.4M $ 228.1M $ · 290K €
- Share of capital
- 29.9 % of 217.9M shares on Jul 31, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Nationwide Small Cap Index Fund Nationwide Mutual Funds | 15,785 | 48.9K $ | 0.02 % | 0.01 % | as of Jul 31, 2026 ↗ |
| iShares Total U.S. Stock Market Index Fund BlackRock Funds | 15,476 | 48K $ | 0.00 % | 0.01 % | as of Jul 31, 2026 ↗ |
| EQ/Morgan Stanley Small Cap Growth Portfolio EQ Advisors Trust | 14,619 | 54.8K $ | 0.01 % | 0.01 % | as of Jun 30, 2026 ↗ |
| Invesco NASDAQ Future Gen 200 ETF Invesco Exchange-Traded Fund Trust II | 14,310 | 51.5K $ | 0.27 % | 0.01 % | as of May 31, 2026 ↗ |
| Venerable Small Cap Index Fund Venerable Variable Insurance Trust | 14,234 | 53.4K $ | 0.02 % | 0.01 % | as of Jun 30, 2026 ↗ |
| VIP Extended Market Index Portfolio Variable Insurance Products Fund II | 14,219 | 53.3K $ | 0.01 % | 0.01 % | as of Jun 30, 2026 ↗ |
| Goldman Sachs Absolute Return Tracker Fund GOLDMAN SACHS TRUST | 13,618 | 51.1K $ | 0.00 % | 0.01 % | as of Jun 30, 2026 ↗ |
| Dimensional US Core Equity 1 ETF Dimensional ETF Trust | 12,796 | 39.7K $ | 0.00 % | 0.01 % | as of Jul 31, 2026 ↗ |
| 1290 VT Small Cap Value Portfolio EQ Advisors Trust | 12,774 | 47.9K $ | 0.01 % | 0.01 % | as of Jun 30, 2026 ↗ |
| Voya VACS Index Series SC Portfolio Voya VARIABLE PORTFOLIOS INC | 12,133 | 45.5K $ | 0.02 % | 0.01 % | as of Jun 30, 2026 ↗ |
| Invesco Nasdaq Biotechnology ETF Invesco Exchange-Traded Fund Trust II | 8,930 | 32.1K $ | 0.05 % | 0.00 % | as of May 31, 2026 ↗ |
| PD Small-Cap Growth Index Portfolio PACIFIC SELECT FUND | 8,807 | 33K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| iShares Morningstar Small-Cap ETF iShares Trust | 8,428 | 26.1K $ | 0.01 % | 0.00 % | as of Jul 31, 2026 ↗ |
| SmallCap Growth Fund I Principal Funds, Inc | 8,388 | 26K $ | 0.00 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Strategic Equity Allocation Trust John Hancock Variable Insurance Trust | 7,879 | 29.5K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| U.S. Social Core Equity 2 Portfolio DFA INVESTMENT DIMENSIONS GROUP INC | 7,723 | 23.9K $ | 0.00 % | 0.00 % | as of Jul 31, 2026 ↗ |
| PD Small-Cap Value Index Portfolio PACIFIC SELECT FUND | 7,173 | 26.9K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| ProShares Ultra Nasdaq Biotechnology ProShares Trust | 6,265 | 22.6K $ | 0.03 % | 0.00 % | as of May 31, 2026 ↗ |
| EQ/Franklin Small Cap Value Managed Volatility Portfolio EQ Advisors Trust | 6,253 | 23.4K $ | 0.01 % | 0.00 % | as of Jun 30, 2026 ↗ |
| SmallCap Value Fund II Principal Funds, Inc | 6,060 | 18.8K $ | 0.00 % | 0.00 % | as of Jul 31, 2026 ↗ |
| iShares MSCI World Small-Cap ETF iShares Trust | 5,815 | 20.9K $ | 0.00 % | 0.00 % | as of May 31, 2026 ↗ |
| Penn Series Small Cap Index Fund Penn Series Funds Inc | 5,200 | 19.5K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| State Street Total Return V.I.S. Fund STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 4,493 | 16.8K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| VIP Total Market Index Portfolio Variable Insurance Products Fund II | 4,367 | 16.4K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Nationwide Fundamental All Cap Equity Portfolio Nationwide Mutual Funds | 4,347 | 13.5K $ | 0.00 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Fidelity SAI Sustainable Sector Fund Fidelity Summer Street Trust | 4,241 | 15.3K $ | 0.00 % | 0.00 % | as of May 31, 2026 ↗ |
| Small-Cap Equity Portfolio PACIFIC SELECT FUND | 3,973 | 14.9K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Pacer WealthShield ETF Pacer Funds Trust | 3,697 | 11.5K $ | 0.05 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Total Stock Market Index Trust John Hancock Variable Insurance Trust | 3,398 | 12.7K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| TIAA Separate Account VA-1 - Stock Index Account TIAA Separate Account VA-1 | 3,391 | 12.7K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| ULTRA SMALL CAP PROFUND ProFunds | 2,291 | 7.1K $ | 0.01 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Dimensional US Vector Equity ETF Dimensional ETF Trust | 1,429 | 4.4K $ | 0.00 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Knights of Columbus U.S. ALL CAP INDEX FUND ADVISORS' INNER CIRCLE III | 1,167 | 3.6K $ | 0.00 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Russell 2000 2x Strategy Fund Rydex Dynamic Funds | 957 | 3.6K $ | 0.01 % | 0.00 % | as of Jun 30, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 731 | 2.7K $ | 0.01 % | 0.00 % | as of Jun 30, 2026 ↗ |
| State Street Balanced Index Fund STATE STREET INSTITUTIONAL INVESTMENT TRUST | 559 | 2.1K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 478 | 1.8K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 441 | 1.7K $ | 0.01 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Dimensional U.S. Marketwide Value ETF Dimensional ETF Trust | 282 | 874.2 $ | 0.00 % | as of Jul 31, 2026 ↗ | |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 263 | 986.3 $ | 0.01 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 202 | 757.5 $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 150 | 465 $ | 0.01 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 51 | 191.3 $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 290K € | 0.35 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Fidelity Disruptive Medicine ETF Fidelity Covington Trust | 0.98 % | as of May 31, 2026 ↗ |
| First Trust Dow Jones Select MicroCap Index Fund First Trust Exchange-Traded Fund | 0.85 % | as of Jun 30, 2026 ↗ |
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 0.69 % | as of Jul 31, 2026 ↗ |
| iShares Genomics Immunology and Healthcare ETF iShares Trust | 0.61 % | as of Jul 31, 2026 ↗ |
| Tema Oncology ETF Tema ETF Trust | 0.47 % | as of May 31, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 0.35 % | as of Dec 31, 2025 ↗ |
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 0.35 % | as of Jul 31, 2026 ↗ |
| Formidable ETF ETF Opportunities Trust | 0.34 % | as of Jun 30, 2026 ↗ |
| Select Health Care Portfolio Fidelity Select Portfolios | 0.31 % | as of May 31, 2026 ↗ |
| VIP Health Care Portfolio Variable Insurance Products Fund IV | 0.28 % | as of Jun 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 143 | +67 | 65,086,859 | +47.6 % |
| 2026Q2 | 76 | +12 | 44,092,939 | +18.4 % |
| 2026Q1 | 64 | +20 | 37,255,847 | +37.3 % |
| 2025Q4 | 44 | +12 | 27,133,848 | +26.5 % |
| 2025Q3 | 32 | +10 | 21,454,542 | +212.9 % |
| 2025Q2 | 22 | -3 | 6,856,745 | -4.9 % |
| 2025Q1 | 25 | -4 | 7,207,122 | +1.8 % |
| 2024Q4 | 29 | +2 | 7,081,811 | +6.6 % |
| 2024Q3 | 27 | 0 | 6,645,271 | +0.4 % |
| 2024Q2 | 27 | -3 | 6,615,762 | +12.0 % |
| 2024Q1 | 30 | -6 | 5,906,847 | -12.4 % |
| 2023Q4 | 36 | 6,741,826 |
Institutional managers
172 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| FMR LLC | 31,955,637 | 150.2M $ | as of Mar 31, 2026 |
| Kynam Capital Management, LP | 15,013,093 | 70.6M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 10,202,785 | 48M $ | as of Mar 31, 2026 |
| PERCEPTIVE ADVISORS LLC | 10,098,824 | 47.5M $ | as of Mar 31, 2026 |
| Venrock Adviser, LLC | 9,982,124 | 46.9M $ | as of Mar 31, 2026 |
| Point72 Asset Management, L.P. | 7,875,390 | 37M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 5,663,408 | 26.6M $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 5,406,193 | 25.4M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 5,228,280 | 24.6M $ | as of Mar 31, 2026 |
| BAKER BROS. ADVISORS LP | 4,975,826 | 23.4M $ | as of Mar 31, 2026 |
| Elmind Capital, LP | 4,550,000 | 21.4M $ | as of Mar 31, 2026 |
| Nextech Invest, Ltd. | 4,449,932 | 20.9M $ | as of Mar 31, 2026 |
| MARSHALL WACE, LLP | 4,138,176 | 19.4M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 3,660,190 | 17.2M $ | as of Mar 31, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 3,582,985 | 16.8M $ | as of Mar 31, 2026 |
| Siren, L.L.C. | 3,457,711 | 16.3M $ | as of Mar 31, 2026 |
| ADAR1 Capital Management, LLC | 3,410,190 | 16M $ | as of Mar 31, 2026 |
| Eversept Partners, LP | 3,188,514 | 15M $ | as of Mar 31, 2026 |
| UBS Group AG | 3,120,155 | 14.7M $ | as of Mar 31, 2026 |
| Jefferies Financial Group Inc. | 3,067,864 | 14.4M $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 2,710,156 | 12.7M $ | as of Mar 31, 2026 |
| Qube Research & Technologies Ltd | 2,249,583 | 10.6M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,066,612 | 9.7M $ | as of Mar 31, 2026 |
| Woodline Partners LP | 2,000,825 | 9.4M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 1,930,920 | 9.1M $ | as of Mar 31, 2026 |
Declared shareholders of CYTOMX THERAPEUTICS INC
There are 5 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Kynam Capital Management, LP and 2 others | 9.96 % | 0 | as of Jun 30, 2026 · SCHEDULE 13G |
| BlackRock, Inc. | 7.60 % | 16,551,452 | as of Jun 30, 2026 · SCHEDULE 13G |
| BANK OF AMERICA CORP /DE/ | 7.00 % | 15,134,689 | as of Jun 30, 2026 · SCHEDULE 13G |
| STATE STREET CORPORATION | 5.40 % | 11,747,236 | as of Jun 30, 2026 · SCHEDULE 13G |
| Point72 Asset Management, L.P. and 2 others | 3.60 % | 7,811,033 | as of Jun 30, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of CYTOMX THERAPEUTICS INC". https://titelia.com/en/stocks/cytomx-therapeutics-inc-US23284F1057